US Food and Drug Administration (FDA) has granted 510(k) clearance for Hospira’s Plum 360 infusion system with Hospira MedNet safety software.
The Plum 360 system builds on the air management and secondary delivery features of Plum A+. It is expected to expand the company’s drug library and wireless capability to enable streamlined electronic medical record (EMR) integration.
The infusion device with Hospira MedNet safety software was developed to improve the efficiency of intravenous (IV) medication administration.
Hospira Medical Devices president David Endicott said: "Hospira is excited to announce clearance of the Plum 360 infusion system in the US, another important milestone in our continued path to streamline and modernise our device portfolio.
"Hospira will continue to develop and launch the most technologically advanced infusion pumps in the industry for our customers and patients."
The system’s smart secondary delivery feature allows the pump to differentiate between primary and secondary infusion lines, and deliver each as intended.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIn addition, the system’s improved wireless communication will accelerate drug library updates and optimise EMR connectivity with automated programming and documentation.
The company’s other product portfolio includes Plum A+ infusion system, Sapphire ambulatory infusion system, SapphirePlus large-volume general-infusion device and LifeCare PCA pain management pump with Hospira MedNet.
According to the company, the Plum 360 infusion system will be fully available to customers in the US in the next few weeks.